CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gao, Yan ^a,b   Feng, Yong ^a   Shen, Jacson K ^a   Lin, Min ^a   Choy, Edwin ^a   Cote, Gregory M ^a   Harmon, David C ^a   Mankin, Henry J ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; HERMES ANTIGEN; MESSENGER RNA; MICRORNA; MIRN199 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; BINDING SITE; BIOLOGICAL MODEL; BONE NEOPLASMS; CHEMISTRY; DISEASE COURSE; DOWN REGULATION; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; METASTASIS; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PATHOLOGY; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE;

3' UNTRANSLATED REGIONS; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; RNA INTERFERENCE; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84935839845     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11365     Document Type: Article

References (39)

1. Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531-1543 (2009).
2. Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat Res 152, 3-13 (2009).
3. Osborne, T. S. & Khanna, C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 146, 132-142 (2012).
4. Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P. & Serra, M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15, 615-634 (2010).
5. Meyers, P. A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9, 1035-1049 (2009).
6. Fletcher, C. D. M. WHO Classification of Tumours of Soft Tissue and Bone, (IARC Press, 2013).
7. Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4, 33-45 (2003).
8. Naor, D., Nedvetzki, S., Golan, I., Melnik, L. & Faitelson, Y. CD44 in cancer. Crit Rev Clin Lab Sci 39, 527-579 (2002).
9. Weber, G. F. et al. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62, 2281-2286 (2002).
10. Gvozdenovic, A. et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 28, 838-847 (2013).
11. Shiratori, H., Koshino, T., Uesugi, M., Nitto, H. & Saito, T. Acceleration of lung metastasis by up-regulation of CD44 expression in osteosarcoma-derived cell transplanted mice. Cancer Lett 170, 177-182 (2001).
12. Ryan, B. M., Robles, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10, 389-402 (2010).
13. Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17, 211-215 (2011).
14. Ishimoto, T. et al. Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. Carcinogenesis 35, 1003-1011 (2014).
15. Duan, Z. et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 10, 1337-1345 (2011).
16. Miwa, S. et al. Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft. PLoS One 8, e71362 (2013).
17. Brown, R. L. et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121, 1064-1074 (2011).
18. Su, Y. J., Lai, H. M., Chang, Y. W., Chen, G. Y. & Lee, J. L. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 30, 3186-3199 (2011).
19. Miletti-Gonzalez, K. E. et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65, 6660-6667 (2005).
20. Chen, H., Hao, J., Wang, L. & Li, Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101, 432-440 (2009).
21. Gao, Y. et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 6, 9313-9326 (2015).
22. Meyers, P. A. & Gorlick, R. Osteosarcoma. Pediatr Clin North Am 44, 973-989 (1997).
23. Gorlick, R. & Khanna, C. Osteosarcoma. J Bone Miner Res 25, 683-691 (2010).
24. Cain, J. W. et al. Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res 9, 637-647 (2011).
25. Lakshman, M., Subramaniam, V., Rubenthiran, U. & Jothy, S. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol 77, 18-25 (2004).
26. Dieudonne, F. X., Marion, A., Hay, E., Marie, P. J. & Modrowski, D. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 70, 5399-5408 (2010).
27. Kayastha, S. et al. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5, 1073-1076 (1999).
28. Ween, M. P., Oehler, M. K. & Ricciardelli, C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 12, 1009-1029 (2011).
29. Kuryu, M. et al. Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 125, 646-652 (1999).
30. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6, 259-269 (2006).
31. Huang, Q. et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10, 202-210 (2008).
32. Song, B. et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28, 4065-4074 (2009).
33. Song, B. et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 9, 96 (2010).
34. Tian, R. et al. miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL. Am J Cancer Res 4, 738-750 (2014).
35. Ouyang, L. et al. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol 30, 340 (2013).
36. Fornari, F. et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70, 5184-5193 (2010).
37. Kim, S. et al. MicroRNA miR-199a∗ regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 283, 18158-18166 (2008).
38. Henry, J. C. et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 403, 120-125 (2010).
39. Cheng, W., Liu, T., Wan, X., Gao, Y. & Wang, H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 279, 2047-2059 (2012).